Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NuriPro
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : NUCLIDIUM
Deal Size : Undisclosed
Deal Type : Partnership
NUCLIDIUM and Guerbet Form Strategic Partnership for Copper-based Radiotheranostics
Details : NUCLIDIUM and Guerbet will support the advancement of targeted copper-based radiotheranostics, 61Cu-based NuriPro, which binds specifically to PSMA, for the treatment of prostate cancer.
Product Name : NuriPro
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : NuriPro
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : NUCLIDIUM
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Gadopiclenol
Therapeutic Area : Oncology
Study Phase : Phase IV
Recipient : University of Massachusetts, Worcester
Deal Size : Inapplicable
Deal Type : Inapplicable
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2024
Lead Product(s) : Gadopiclenol
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Recipient : University of Massachusetts, Worcester
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadopiclenol
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas
Details : Undisclosed
Product Name : Elucirem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Gadopiclenol
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadopiclenol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Bracco
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2023
Lead Product(s) : Gadopiclenol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Bracco
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadopiclenol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment
Details : Undisclosed
Product Name : Elucirem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : Gadopiclenol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadopiclenol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : Gadopiclenol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2022
Lead Product(s) : Gadopiclenol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Safety of Gadopiclenol in Japanese Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2021
Lead Product(s) : Gadopiclenol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iodized Oil
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Recipient : Assistance Publique – Hôpitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Lipiodol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2021
Lead Product(s) : Iodized Oil
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Recipient : Assistance Publique – Hôpitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Bayer AG | Bracco | GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2020
Lead Product(s) : Gadolinium Ethoxybenzyl Dtpa
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Bayer AG | Bracco | GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable